Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.62 |
| ▸ | DRD3 | P35462 | 10/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913794 | 1.00 | DRD2 (0.62) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL14494898 | 0.79 | DRD2 (0.67) | DRD2DRD3DRD4 | |
| SCHEMBL22302290 | 0.79 | DRD2 (0.59) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL30579521 | 0.77 | DRD2 (0.57) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL1896873 | 0.77 | DRD2 (0.72) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL1310960 | 0.76 | DRD2 (1.00) | DRD2DRD3DRD4SLC6A4 | |
| SCHEMBL22303311 | 0.76 | DRD2 (0.55) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL20672353 | 0.76 | DRD2 (1.00) | DRD2DRD3DRD4SLC6A4 | |
| SCHEMBL2034152 | 0.76 | DRD2 (1.00) | DRD2DRD3DRD4SLC6A4 | |
| SCHEMBL28901990 | 0.76 | DRD2 (0.55) | DRD2DRD3DRD4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778685-B1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
| EP-1778685-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2007-05-02 | — | — | EP | disclosed |
| EP-1771448-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006050976-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006015737-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299091-A1 | Azaindole Carboxamides | TPH1, TPH2, HTR1A | DRD2 64/4885DRD3 176/4885DRD4 94/4885 |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | GRIN2A, GRIN2C, GRIN1 | DRD2 248/4885DRD3 474/4885DRD4 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.